Jacob Pontoppidan Thyssen

Enterprise-level R&D executive and physician-scientist with 20+ years of clinical and scientific leadership and 3+ years in C-suite pharma roles. Proven track record in R&D strategy, portfolio and capital prioritization, clinical development decision-making, and external partnerships across biotech, mid-size and large pharma. Deep expertise in immunology and inflammation, spanning biologics, small molecules and topical therapies. Experienced leader operating at the interface of science, capital, governance and corporate strategy. For 10 years, a consultant for biotech and pharmaceutical industry. Provided critical input to clinical trial design and analysis, outcome measurement development, real world evidence generation and dissemination strategies, and was part of data safety monitoring boards and gave testimony to regulatory authorities, e.g. the PRAC for JAKi by EMA. Main area of expertise immunology and inflammation. Advanced key topical, biological and small molecule programs for big pharma and biotech. EXECUTIVE EXPERIENCE Full accountability for R&D strategy and early development portfolio across preclinical and clinical programs during a turn around. Member of executive leadership team; close collaboration with CEO, CFO, BD and Board. Defined portfolio prioritization frameworks, go/no-go decision processes and scientific investment strategy. Oversight of biologics, oral small molecules and topical programs from discovery to early clinical development. Led and developed senior scientific and clinical leadership teams in a global matrix organization. Active involvement in external partnerships, scientific alliances, regulatory interactions and due diligence. ACADEMIC & CLINICAL LEADERSHIP (SELECTED) Professor Emeritus, University of Copenhagen (2023–present) Tenured Professor, University of Copenhagen (2017–2023) Chief Physician, Bispebjerg & Gentofte University Hospitals (2015–2023) Led internationally recognized translational research programs in inflammatory skin diseases; extensive experience bridging clinical science, real-world evidence and regulatory decision-making. Former head of international research group; supervised 30+ PhD students 750 peer-reviewed publications; H-index >70 Author/editor of major textbooks (Springer) Research funding >40 m DKK from Novo Nordisk, Lundbeck, LEO Foundation Inventor of diagnostic devices; contributor to international guidelines